| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 18780870 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 106 journal articles in the PubMed database | Email to a friend | | |
| Chlebowski RT, Col N
Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. [Comment, Letter]
J Natl Cancer Inst 2008 Sep 17; 100(18):1331-2; author reply 132-3.
Full Citation | Publisher Full Text | Find Related Articles | | Gurwitz D, Newman W
Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. [Comment, Letter]
J Natl Cancer Inst 2008 Sep 17; 100(18):1331; author reply 1332-4.
Full Citation | Publisher Full Text | Find Related Articles | | Punglia RS, Burstein HJ, Winer EP, et al.
Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. [Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't]
J Natl Cancer Inst 2008 May 7; 100(9):642-8.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Cianfrocca M, Wolff AC
Optimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer. [Journal Article]
Oncology (Williston Park) 2007 Jan; 21(1):63-9; discussion 69, 72, 75 passim.
Abstract | Full Citation | Find Related Articles | | Nabholtz JM
Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women. [Journal Article, Review]
Am J Hosp Palliat Care 2004 Nov-Dec; 21(6):457-65.
Abstract | Full Citation | Find Related Articles | | Berruti A, Tucci M, Mosca A, et al.
Changes in bone mineral density after adjuvant aromatase inhibitors and fracture risk in breast cancer patients. [Comment, Letter]
J Clin Oncol 2007 Apr 10; 25(11):1455-6.
Full Citation | Publisher Full Text | Find Related Articles | | Vakaet L
Re: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. [Comment, Letter]
J Natl Cancer Inst 2006 Aug 16; 98(16):1162; author reply 1162-3.
Full Citation | Find Related Articles | | Prowell TM, Stearns V
Extended adjuvant therapy for breast cancer--how much is enough? [Comment, Editorial]
J Natl Cancer Inst 2007 Dec 19; 99(24):1825-7.
Full Citation | Publisher Full Text | Find Related Articles | | Van Poznak CH, Hayes DF
Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only? [Comment, Editorial]
J Natl Cancer Inst 2006 Sep 20; 98(18):1261-3.
Full Citation | Publisher Full Text | Find Related Articles |   |
|
| |
Advertise on this site.
|
